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The bacterial disulfide machinery is an attractive molecular
target for developing new antibacterials because it is required
for the production of multiple virulence factors. The arche-
typal disulfide oxidase proteins in Escherichia coli (Ec) are
DsbA and DsbB, which together form a functional unit: DsbA
introduces disulfides into folding proteins and DsbB re-
oxidizes DsbA to maintain it in the active form. In
Mycobacterium tuberculosis (Mtb), no DsbB homologue is
encoded but a functionally similar but structurally divergent
protein, MtbVKOR, has been identified. Here, the Mtb
protein Rv2969c is investigated and it is shown that it is the
DsbA-like partner protein of MtbVKOR. It is found that it
has the characteristic redox features of a DsbA-like protein: a
highly acidic catalytic cysteine, a highly oxidizing potential and
a destabilizing active-site disulfide bond. Rv2969c also has
peptide-oxidizing activity and recognizes peptide segments
derived from the periplasmic loops of MtbVKOR. Unlike the
archetypal EcDsbA enzyme, Rv2969c has little or no activity
in disulfide-reducing and disulfide-isomerase assays. The
crystal structure of Rv2969c reveals a canonical DsbA fold
comprising a thioredoxin domain with an embedded helical
domain. However, Rv2969c diverges considerably from other
DsbAs, including having an additional C-terminal helix (H8)
that may restrain the mobility of the catalytic helix H1. The
enzyme is also characterized by a very shallow hydrophobic
binding surface and a negative electrostatic surface potential
surrounding the catalytic cysteine. The structure of Rv2969c
was also used to model the structure of a paralogous DsbA-
like domain of the Ser/Thr protein kinase PknE. Together,
these results show that Rv2969c is a DsbA-like protein with
unique properties and a limited substrate-binding specificity.
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1. Introduction
The devastating disease tuberculosis (TB) caused by the
bacterium Mycobacterium tuberculosis (Mtb) is responsible
for approximately two million deaths annually. The loss of
effectiveness of the only available TB vaccine, Bacillus
Calmette–Gue´rin (BCG), for people of economically
productive age (15–59 years) has created an enormous drain
on the world economy (World Health Organization, 2011). A
major hurdle to eradicating TB is the requirement for multi-
antibiotic therapy administered over a period of six to nine
months (Connolly et al., 2007). Multidrug-resistant (MDR)
and extensively drug-resistant (XDR) Mtb strains have
evolved for which therapeutic options are limited to toxic and
expensive second-line and third-line reserved drugs (Phillips,
2013). Aside from MDR and XDR strains, Mtb has evolved
mechanisms to succeed as an intracellular pathogen by
manipulating the host immune signalling responses (Kumar &
Narayanan, 2012; Pieters, 2008). Mtb virulence factors can
avert host-cell apoptosis, phagosome maturation and auto-
phagy to gain intracellular persistence, hence restricting the
adaptive immune response (Vergne et al., 2004; Welin et al.,
2011; Songane et al., 2012; Kim et al., 2012). Considering that
one third of the world’s population is infected with TB, there is
a compelling need to identify new molecular targets for the
development of antituberculosis drugs as alternatives or
additions to the current broad-spectrum traditional antibiotics
(Raman et al., 2012; Murillo et al., 2007; Lou & Zhang, 2010).
Mtb cell-surface and secretory proteins are known virulence
components for mycobacterial growth during infection and for
continued survival in host cells (Zhou et al., 2010; Scherr et al.,
2007; Feltcher et al., 2010; DiGiuseppe Champion & Cox,
2007). Consequently, antivirulence approaches targeting
individual proteins responsible for mycobacterial virulence
are being intensively investigated (Feltcher et al., 2010). While
these approaches offer some advantages, there is also a case to
be made for a therapeutic strategy that interferes with the
early stages of Mtb infection and that affects multiple viru-
lence targets.
Periplasmic disulfide-bond forming (Dsb) enzymes catalyze
the oxidative folding and maturation of many toxins and
surface proteins required for virulence in a range of patho-
genic bacteria (Heras et al., 2009). Typically, Dsb proteins
include a soluble thioredoxin (Trx) fold protein DsbA, which
introduces disulfide bonds into newly translocated proteins in
the periplasm (Heras et al., 2009; Kadokura et al., 2003; Inaba,
2009), and its cognate inner membrane partner protein DsbB
that keeps DsbA in the functionally active oxidized form
(Inaba & Ito, 2008; Inaba et al., 2006). Deletion of DsbA or
DsbB has pleiotropic effects on virulence-factor production
and in some cases can provide a marginal increase in sensi-
tivity to conventional antibiotics (Hayashi et al., 2000). Both
DsbA and DsbB have therefore been identified as potential
antibacterial targets to combat virulence of pathogenic
bacteria (Heras et al., 2009; Yu, 1998). DsbA and DsbB
enzymes are not always conserved across bacterial species,
although the oxidative-folding pathway seems to be widely
required for bacterial virulence (Dutton et al., 2008).
Approximately 60% of Mtb exported proteins are esti-
mated to require a disulfide bond for activity, stability and
protease resistance (Chim et al., 2011; Goulding et al., 2004).
However, the mycobacterial genome is deficient in a DsbB
sequence homologue. Moreover, a DsbA-like protein
responsible for disulfide oxidase activity has not been
confirmed in Mycobacterium, although the Mtb gene product
of Rv2969c (annotated as uncharacterized) has been identified
as a potential candidate DsbA (Wang et al., 2011). DsbA
enzymes typically comprise two domains: a noncontiguous Trx
domain, which has a characteristic redox-active CXXC motif
and a cis-Pro motif, and a helical domain inserted into the Trx
domain. Aside from the Trx domain motifs, sequence
conservation among DsbA enzymes is very low. The Mtb
genome contains two genes encoding remote DsbA homo-
logues, Rv2969c and a transmembrane serine/threonine
protein kinase protein incorporating a DsbA-like domain
(PknE; Rv1743; I6YBI4).
A gene adjacent to the dsbA-like Rv2969c gene encodes a
mammalian homologue of vitamin K epoxide reductase
(VKOR; Rv2968c; Dutton et al., 2008). In humans, deficiency
of VKOR or administration of its antagonist warfarin inhibits
reduction of vitamin K 2,3-epoxide that is otherwise required
for blood clotting. In an elegant series of studies, the Beckwith
group proposed that MtbVKOR may represent the functional
equivalent of E. coli DsbB (EcDsbB) and showed that
MtbVKOR rescues motility of E. coli dsbB null cells (Dutton
et al., 2008; Wang et al., 2011). This notion was further
supported by the observation that some plants and bacteria
encode a Trx-VKOR fusion protein. A crystal structure of a
Cyanobacterium Trx-VKOR fusion confirmed that VKOR and
DsbB are functionally similar but structurally divergent (Li et
al., 2010).
Throughout Mycobacterium, Rv2969c and VKOR are
genetically linked. This may indicate that they are functionally
related genes. Genome-wide transposon-insertion mutagen-
esis studies showed that these two genes are essential for the
optimal growth of Mtb (Sassetti et al., 2003). This is in
agreement with the observation that deletion of VKOR in
M. smegmatis confers severe growth defects (Wang et al.,
2011). Moreover, the anticoagulant medication warfarin can
inhibit growth of Mtb in a VKOR-dependent manner (Dutton
et al., 2010).
Here, we present a detailed structural and functional char-
acterization of Rv2969c, the remote DsbA homologue
encoded by Mtb (which we refer to as MtbDsbA). The
structure of MtbDsbA reveals a number of modifications to
the archetypal EcDsbA structure and to the binding surface
surrounding the active-site cysteine. The in vitro activity of
MtbDsbA indicates that it is a mycobacterial disulfide oxidase
and its ability to bind peptides derived from MtbVKOR
supports the notion that MtbDsbA and MtbVKOR form a
functional redox pair. MtbDsbA may therefore represent an
important target for the development of antituberculosis
drugs that block oxidative folding of exported Mtb proteins
necessary for mycobacterial infection and survival within host
macrophages. The structure that we report may serve as a
starting point for rational drug design towards this end.
2. Experimental procedures
2.1. Cloning, expression and protein production
The N-terminal region of MtbDsbA is predicted to be a
secretion signal (SignalP; Emanuelsson et al., 2007) or trans-
membrane anchor (TMHMM; Krogh et al., 2001). A codon-
optimized synthetic gene corresponding to the soluble
MtbDsbA enzyme lacking this region (M. tuberculosis H37Rv,
residues 46–255) was inserted into the bacterial expression
vector pMCSG7 by ligation-independent cloning (Eschenfeldt
et al., 2009). An amino-terminal His6-tagged MtbDsbA was
expressed in E. coli BL21(DE3) cells using auto-induction
medium (Studier, 2005). Protein was purified using TALON
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cobalt resin (Clontech) and the His6 tag was removed by TEV
protease leaving three vector-derived residues (Ser-Asn-Ala)
at the N-terminus. For crystallization experiments, the protein
was incubated with 100 mM oxidized glutathione to generate
the oxidized enzyme, prior to final purification on a Superdex
75 gel-filtration column (GE Healthcare). Site-directed
mutagenesis was performed using the QuikChange method
and the mutation was confirmed by DNA sequencing. A
noncatalytic double cysteine mutant MtbDsbAm (Cys140Ala,
Cys192Ala) and an active-site single cysteine mutant
MtbDsbA (Cys92Ala) were expressed and purified in the
same way as for wild-type MtbDsbA.
2.2. Crystallization and diffraction data collection
MtbDsbA crystals were grown by the hanging-drop vapour-
diffusion method at 293 K; drops were set up using a Mosquito
crystallization robot (TTP Labtech) and were incubated and
imaged in a RockImager 1000 (Formulatrix). 250 nl MtbDsbA
solution concentrated to 55 mg ml1 in 25 mMHEPES pH 7.4,
100 mM NaCl was mixed with 250 nl reservoir solution
consisting of 2.4M sodium malonate pH 5.5, 3.7% 1,4-
dioxane, 0.08% polyvinylpyrrolidone. Crystals grew as long
thin rods (30  500 mm) in 3–4 weeks and were flash-cooled
in liquid nitrogen after brief rinsing in 3.4M sodium malonate
pH 5.5. Diffraction data were collected on the MX2 beamline
at the Australian Synchrotron at a wavelength of 0.9537 A˚ and
were recorded using an ADSC Quantum 315r detector
controlled by Blu-Ice (McPhillips et al., 2002). Data were
integrated in XDS (Kabsch, 2010), space-group possibilities
were analyzed using POINTLESS (Evans, 2006) and data
were scaled in SCALA from the CCP4 suite (Winn et al.,
2011).
2.3. Structure determination and refinement
Molecular-replacement (MR) searches for MtbDsbA with
Phaser (McCoy et al., 2007) using intact DsbA templates (less
than 21% sequence identity) were unsuccessful. Regions
contributing to DsbA structural divergence were identified by
superposition of DsbA structures currently available in the
PDB and the structurally divergent regions were trimmed to
generate a collection of DsbA ‘Poly Ser’ MR templates
(nonglycine and non-alanine residues that were not conserved
were changed to serine) for MR trials in Phaser. A Poly Ser
conserved structural core search model derived from
Staphylococcus aureus DsbA (SaDsbA) (PDB entry 3bci;
Heras et al., 2008) gave an MR solution (TFZ = 8.0) with two
copies in the asymmetric unit. This trimmed MR search model
provided 39% coverage with 48% identity to the MtbDsbA
sequence (Supplementary Fig. S11). Iterative manual building,
density modification and refinement in PHENIX (Adams et
al., 2010) and Coot (Emsley & Cowtan, 2004) allowed tracing
of almost the entire MtbDsbA sequence. Final refinement
cycles involving TLS were carried out in phenix.refine.
Electron density was absent for the three vector-derived
residues and the N-terminal 11 residues of the MtbDsbA
construct in both molecules in the asymmetric unit. At the
interface of the two MtbDsbA molecules in the asymmetric
unit, two additional regions of electron density were observed
in the difference Fourier map contoured at 3.0. These were
interpreted as 1,4-dioxane and HEPES, both of which were
present in the crystallization condition. A summary of the
data-processing and refinement statistics is presented in Table
1. The stereochemical quality of the final model was assessed
using AutoDep Input Tool (Yang et al., 2004), MolProbity
(Chen et al., 2010) and SFCHECK (Vaguine et al., 1999). The
coordinates and structure factors have been deposited in the
Protein Data Bank (PDB entry 4k6x).
2.4. Isothermal titration calorimetry (ITC)
Experiments were carried out on a Microcal Auto-iTC200
(GE Healthcare). Peptides with N-terminal acetylation and
C-terminal amidation were chemically synthesized manually
by classic solid-phase peptide synthesis using rink amide
MBHA resin (ChemImpex International, loading
0.65 mmol g1) and Fmoc-protected amino acids (ChemImpex
International). Peptides were purified by reversed-phase
HPLC (C18, Phenomenex) and characterized by retention
times, electrospray mass spectrometry and 1H NMR spectro-
scopy. Each ITC titration involved an initial 0.5 ml injection
(not included in the subsequent analysis) followed by 19
injections of 2 ml of 2–4 mM peptide into cells containing
100 mMMtbDsbA in 25 mM HEPES pH 7.4, 100 mM NaCl at
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Table 1
Summary of data-collection and refinement statistics.
Values in parentheses are for the highest resolution shell.
Space group I4122
Unit-cell parameters (A˚) a = 92.05, b = 92.05, c = 232.76
Data-collection wavelength (A˚) 0.9537
Resolution range (A˚) 85.6–1.97 (2.08–1.97)
No. of observations 286100 (39641)
No. of unique reflections 35185 (5080)
Mean I/(I) 14.9 (3.3)
Rmerge 0.096 (0.66)
Rp.i.m. 0.036 (0.246)
Multiplicity 8.1 (7.8)
Wilson B factor (A˚2) 26.1
Model and refinement statistics
Resolution range (A˚) 59.3–1.97
No. of unique reflections 35175
Completeness 98.4
Rwork (%) 14.5 (20.3)
Rfree† (%) 19.2 (28.4)
No. of non-H atoms
Protein 2996
Ligand 17
Water 415
R.m.s.d., bond lengths (A˚) 0.011
R.m.s.d., bond angles () 1.27
Ramachandran favoured/allowed (%) 97.5/99.5
Average B factor (A˚2)
Protein 23.7
Ligand 24.6
Water 34.6
† Rfree is calculated as for Rwork but for 5% of the total reflections chosen at random and
omitted from refinement.
1 Supplementary material has been deposited in the IUCr electronic archive
(Reference: TZ5033). Services for accessing this material are described at the
back of the journal.
298 K. Thermodynamic parameters were obtained from
nonlinear curve fitting using a single-site binding mode in
Origin 7.0 (SR4 v7.0552 beta, Microcal).
2.5. Thermal stability measurement
Temperature-induced unfolding of MtbDsbA was recorded
by far-UV circular dichroism (CD), with the temperature
increasing from 298 to 368 K at a rate of 1 K min1 using a
Jasco J-810 spectropolarimeter. The normalized CD signal for
oxidized (219 nm) and reduced (220.5 nm) MtbDsbA in
100 mM phosphate buffer, 1 mM ethylenediaminetetraacetic
acid (EDTA) pH 7.0 was fitted to a two-state unfolding model
as described previously (Kurz et al., 2009). The redox status of
the oxidized and reduced protein preparation with oxidized
glutathione and DTT (dithiothreitol), respectively, was veri-
fied with Ellman’s reagent.
2.6. Insulin-reduction assay
The catalytic ability of MtbDsbA to reduce insulin in the
presence of DTTwas monitored by the increase in absorbance
at 650 nm over 80 min as described previously (Heras et al.,
2008). Briefly, the reaction mixture contained 131 mM insulin
and 10 mM of oxidized MtbDsbA or EcDsbA in 100 mM
phosphate buffer pH 7.0, 2 mM EDTA. The reaction was
initiated by adding DTT to a final concentration of 0.35 mM.
The noncatalyzed aggregation of insulin by DTT was moni-
tored in a control reaction without enzyme.
2.7. Isomerization of scrambled RNaseA
In vitro disulfide isomerase activity of MtbDsbA, EcDsbC
and EcDsbA was monitored using a scrambled RNaseA
refolding assay (Hillson et al., 1984). Scrambled RNaseA was
produced as previously described (Heras et al., 2008).
Isomerization of scrambled RNaseA (40 mM) was conducted
in 100 mM sodium phosphate buffer containing 1 mM EDTA
pH 7.0, 10 mM DTT and 10 mM DsbA or DsbC at 298 K
(750 ml). At various time intervals, 50 ml of refolded RNase
sample was taken to monitor the hydrolysis activity of cytidine
30,50-cyclic monophosphate (3 mM) using a BioTek H1 plate
reader at 296 nm. Native RNaseA and scrambled RNaseA in
the absence of DsbA or DsbC served as positive and negative
controls, respectively.
2.8. Ubiquinone-reduction assay
DsbB-catalyzed oxidation of DsbA can be monitored by
following the decrease in ubiquinone absorbance at 275 nm
(Bader et al., 2000). The reaction mixture (70 ml) contained
30 mM reduced MtbDsbA or EcDsbA, 30 mM ubiquinone-1
(UQ1) in 50 mM Tris pH 7.0, 100 mM NaCl and 0.01%
n-dodecyl -d-maltoside. The decrease in absorbance was
recorded for 3 min at 303 K after addition of 57 nM EcDsbB
using a Varian Cary 50 UV–visible spectrophotometer.
2.9. Determination of redox potential
Oxidized MtbDsbAm (2 mM) was incubated in 200 ml
degassed buffer consisting of 100 mM phosphate buffer, 1 mM
EDTA pH 7.0, 1 mM oxidized glutathione (GSSG) for 1 h at
room temperature. The protein was then incubated in buffers
with a range of reduced glutathione (GSH) concentrations
(0.01 mM–1 mM) for 24 h at 298 K (10 ml per reaction
containing 2 mM protein concentration). After incubation, the
reactions were stopped with 10% trichloroacetic acid and the
precipitated protein pellets were collected by centrifugation at
14 000 rev min1 for 10 min at 277 K. The pellets were washed
with 100% ice-cold acetone and dissolved in buffer consisting
of 50 mM Tris pH 7.0, 1% SDS, 4 mM 4-acetamido-40-male-
imidylstilbene-2,20-disulfonate (AMS) to label the free thiols.
Separation of reduced and oxidized forms was performed on a
NuPAGE 12% bis-tris gel (1.0 mm thick, 12 well; Invitrogen,
Australia). The gel was stained with Coomassie, scanned
(Perfection V700 Scanner, Epson) and intensities of the
reduced protein were analyzed using ImageJ v.1.42q
(Schneider et al., 2012). The fraction of the reduced protein
was plotted against the ratio [GSH]2/[GSSG] and the equili-
brium constant Keq was calculated using the binding equation
Y = ([GSH]2/[GSSH])/{Keq + ([GSH]
2/[GSSH])}, where Y is
the fraction of reduced protein at equilibrium. The redox
potential was calculated using the Nernst equation E0
0
=
E0
0
GSH/GSSG  (RT/nF)lnKeq, where E00GSH/GSSG is the standard
potential of 240 mV (Gilbert, 1995), R is the universal gas
constant 8.314 J K1 mol1, T is the absolute temperature in
K, n is the number of electrons transferred, F is the Faraday
constant 9.648  104 C mol1 and Keq is the equilibrium
constant.
2.10. Determination of pKa
The pH-dependent UV absorbance of the nucleophilic
cysteine thiol was followed at 240 nm (Nelson & Creighton,
1994). Measurements of oxidized or reduced MtbDsbAm
(lacking the second disulfide) of 24 or 16 mM in a total volume
of 200 ml buffer comprising 10 mM dipotassium phosphate,
10 mM monopotassium phosphate, 10 mM sodium citrate,
10 mM Tris, 1 mM EDTA, 200 mM KCl were performed at pH
values ranging from 2.2 to 7.5 using Greiner 96-well UV-Star
microplates. The redox status of the protein preparation was
verified with Ellman’s reagent. The absorbance at 240 and
280 nm was recorded on a BioTek Synergy H1 microplate
reader and corrected for blank absorbance. The pH-depen-
dent thiolate-specific absorbance signal [(A240/A280)reduced/
(A240/A280)oxidized] was fitted to the Henderson–Hasselbach
equation as described previously (Kurz et al., 2009).
2.11. Complementation assay
Complementation of EcDsbA by MtbDsbAwas monitored
in a cell-swarming assay as described previously (Kurz et al.,
2009). A chimeric gene encoding an EcDsbA signal peptide
fused to the mature form of MtbDsbA was cloned into the
arabinose-inducible pBAD33 vector (Guzman et al., 1995). A
nonmotile E. coli dsbA mutant (JCB817) strain transformed
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with this chimera construct was stabbed into a minimal agar
(M63) plate supplemented with 40 mg ml1 of each amino
acid and 1 mg ml1 arabinose. The swarming of E. coli cells
was analyzed after incubating the plate for 4–6 h at 303 K.
JCB817 cells transformed with pBAD33::EcDsbA were used
as a positive control. A nonmotile dsbA/dsbB double-
mutant strain (JCB818) served as a negative control. Plates
without arabinose were used to monitor background
complementation.
2.12. Peptide-oxidation assay
A synthetic peptide substrate CQQGFDGTQNSCK with a
europium DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid europium) chelate at the N-terminus and a
methylcoumarin amide at the "-amino group of the lysine was
obtained from Anaspec, USA (for further details of the
peptide, see Vivian et al., 2009). Disulfide-bond formation of
the peptide was fluorometrically followed using time-resolved
fluorescence with excitation at 340 nm and emission at 615 nm,
a delay of 150 ms and a reading time of 100 ms in a Synergy H1
multimode plate reader (BioTek, USA). The assay was
performed in a 384-well white plate (PerkinElmer OptiPlate)
containing EcDsbA or MtbDsbA and 2 mM GSSG in 50 mM
MES, 50 mM NaCl, 2 mM EDTA at pH 5.5. The reaction was
initiated by the addition of substrate peptide at 4–8 mM in a
total volume of 50 ml. The reaction was performed in triplicate
and repeated at various concentrations of EcDsbA or
MtbDsbA. The reaction in the absence of enzyme was used as
a control.
3. Results
3.1. Putative Mtb DsbA-like proteins
To identify potential Mtb DsbA-like oxidases, we searched
the genome of the virulent strain Mtb H37Rv by using
keyword and BLASTP searches. 15 Trx-related gene products
were identified (Table 2) and nine of these were eliminated as
potential DsbA-like proteins as they are likely to be located in
the cytoplasm (on the basis of literature reports, the absence
of sorting signal/transmembrane region and sequence-to-
structure relationships). Of the remaining six predicted to be
extracytoplasmic Trx-related proteins, only the sequences of
hypothetical Rv2969c and the DsbA-like domain of PknE
(Rv1743) remotely resembled DsbA homologues. The
sequence identity of the nearest structurally characterized
neighbour, Bacillus subtilis DsbA (BsDsbA), is less than 19%
(by sequence-based alignment) to these two Mtb DsbA
paralogues. Rv2969c and Rv1743 share 50% sequence
similarity (31% identity) and both contain four conserved
cysteine residues. The sequence positions of two of the four
cysteines are similar to that of the characteristic redox-active
CXXC motif of the Trx fold, whereas the other two cysteines
are consistent with the structural (noncatalytic) cysteines
found in Wolbachia pipientis -DsbA1 (Wp-DsbA1; Kurz et
al., 2009).
The presence of a predicted sorting signal or trans
membrane helix in Rv2969c (currently annotated as
uncharacterized) indicates it is either secreted into, or
membrane-anchored with the catalytic domain facing, the
recently characterized mycobacterial periplasm (Patarroyo et
research papers
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Table 2
Survey of Trx-related proteins in M. tuberculosis strain H37Rv.
Summary of the 15 Trx-related proteins found using keyword and BLASTP searches. Only Rv2969c and Rv1743 could be considered similar to DsbA-like proteins.
Structural similarities to Trx-related proteins were identified using BLASTP and Fold and Function Assignment (FFAS; http://ffas.burnham.org/) searches against
PDB codes or % identity to reported structure (PDB code in parentheses) are given. The functional annotation, presence and location of signal peptide/
membrane-spanning region and operon are derived information from Target TB annotation (http://genome.tbdb.org/). The presence of signal sequence and
transmembrane region were also confirmed using SignalP3.0 and transmembrane prediction using hidden Markov models (TMHMM). DsbA-like (Rv2969c) is
predicted to have an N-terminal transmembrane (TM) helix or signal peptide (SP).
Protein Length Functional annotation Signal peptide Structural representative Operon
PknE-DsbA (Rv1743) 566 Ser/Thr kinase Integral
membrane
2h34 (kinase; Gay et al., 2006),
31% (DsbA-like)
Ser-Thr protein kinase, fused
DsbA-like
DsbA-like (Rv2969c) 255 Conserved, unknown TM or SP Present work Pyruvate carboxylase-like, VKOR,
Dsb-like
DsbE (Rv2878c) 173 Unknown Yes 1lu4 (Goulding et al., 2004) Rv2877c, DsbE
DsbF (Rv1677) 182 Unknown Yes 3ios (Chim et al., 2010) Rv1676, DsbF
ResA-like (Rv3673c) 227 Unknown Yes 30% (DsbE/F) Rv3673c, endonuclease III
Trx-related (Rv0526) 216 Unknown Yes 47% (3lwa; Midwest Center for
Structural Genomics, unpublished work)
HemeL, Rv0525, Rv0526, ccdA,
Rv0528, ccsA
TrxC (Rv3914) 116 Disulfide exchange No 3o6t (Hall et al., 2011) TrxB2, TrxC
TrxB2 (Rv3913) 335 Disulfide reductase No 2a87 (Akif et al., 2005) TrxB2, TrxC
TrxB1 (Rv1471) 123 Disulfide exchange No 36% (3hhv; Ruggiero et al., 2009) TrxA, TrxB1
TrxA (Rv1470) 124 Disulfide exchange No 32% (3hhv; Ruggiero et al., 2009) TrxA, TrxB1
Trx-like (Rv0816c) 140 Disulfide exchange ?? 28% (3ilu; Ptak et al., 2009) Rv0816c, Rv0817c
Trx-like (Rv2183c) 131 Conserved, unknown ?? 14% (3raz; New York SGX Research Center
for Structural Genomics, unpublished work)
Rv2183c, Rv2184c
Trx-fusion protein (Rv1324) 304 Disulfide exchange No 24% (3qdn; Center for Structural Genomics
of Infectious Diseases, unpublished work)
Rv1324
Trx-related (Rv2286c) 230 Conserved, unknown No 20% (3fz5; Midwest Center for Structural
Genomics, unpublished work)
Rv2286c
Trx-related (Rv2466c) 207 Unknown No 14% (3fz5; Midwest Center for Structural
Genomics, unpublished work)
Rv2466c
al., 2008; Sani et al., 2010) and may therefore represent a
potential candidate for a DsbA-like protein. Hereafter, we
refer to it as MtbDsbA. Its paralogue PknE is a single-pass
transmembrane Ser/Thr protein kinase that comprises an
extracytoplasmic DsbA-like domain and a cytoplasmic kinase
domain (Gay et al., 2006). PknE has been shown to regulate
cellular events in response to host-mediated apoptotic stimuli
such as nitric oxide (Jayakumar et al., 2008). As such, PknE
appears to promote the survival of Mtb in the latent state by
suppressing host apoptosis (Kumar & Narayanan, 2012).
3.2. MtbDsbA is highly oxidizing
Typically, DsbA enzymes have a highly acidic catalytic
cysteine and a highly oxidizing redox potential that enable its
participation in thiol–disulfide exchange reactions. To study
the redox characteristics of MtbDsbA, we created a double
noncatalytic cysteine mutant MtbDsbAm (Cys140Ala,
Cys192Ala). Similar to Wp-DsbA1, this mutation did not
affect the solubility and integrity of MtbDsbA. Using a pH-
titration experiment (Fig. 1a), we found that the measured pKa
of the catalytic cysteine Cys89 is 4.2 0.2, which falls between
the previously reported values for EcDsbA (pKa = 3.3) and
Vibrio cholerae DsbA (VcDsbA, pKa = 5.1). The redox
potentials of DsbA proteins also vary among characterized
DsbAs; the most reducing and oxidizing DsbAs reported to
date are Wp-DsbA1 (163 mV) and neisserial NmDsbA3
(80 mV), respectively. We measured the standard redox
potential by equilibration of MtbDsbAm with glutathione at
298 K and pH 7.0 (Fig. 1b). We found that the oxidizing power
of MtbDsbA (99 mV) is comparable to that of Pseudomonas
aeruginosa DsbA (PdDsbA) (94 mV; Shouldice et al., 2010),
somewhat more oxidizing than EcDsbA (122 mM;
Wunderlich & Glockshuber, 1993) and a little less oxidizing
than BsDsbA (80 mM; Crow et al., 2009).
Another characteristic feature common to DsbA enzymes is
that the catalytic cysteine disulfide bond reduces the stability
of the protein (Heras et al., 2008). A thermal unfolding
experiment comparing the stability of the redox forms showed
that the oxidized (disulfide) form of MtbDsbA is less stable
than its reduced form by 13 K (Fig. 1c), which is in agreement
with the findings for other DsbA enzymes.
Taken together, these results show that the putative DsbA
protein encoded byM. tuberculosis has the redox hallmarks of
a DsbA disulfide oxidoreductase.
3.3. MtbDsbA is a disulfide oxidase
An in vivo complementation experiment has been devel-
oped to demonstrate that the expression of a DsbA enzyme
can rescue the motility of E. coli cells deficient in EcDsbA
(Kurz et al., 2009; Paxman et al., 2009). However, MtbDsbA
does not restore the motility of E. coli DsbA null cells as
shown by the results of the cell-swarming assay (Fig. 2a). To
establish whether this might be a consequence of a lack of
interaction between MtbDsbA and EcDsbB (the essential
redox partner of EcDsbA), we monitored the ability of
EcDsbB to oxidize MtbDsbA in an EcDsbB-catalyzed
ubiquinone reduction assay (Fig. 2b). This experiment showed
as expected that EcDsbB can oxidize EcDsbA, but it failed to
redox couple with MtbDsbA. This could explain why
MtbDsbA does not complement EcDsbA in the motility assay,
but we cannot rule out the possibility that MtbDsbA is in-
active because it also does not recognize the P-ring protein
(FlgI) substrate of EcDsbA in the assay (Dailey & Berg,
1993).
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Figure 1
Characterization of the redox properties of MtbDsbA. (a) pKa determination of the nucleophilic cysteine of MtbDsbA. This is a representative plot of
three independent measurements of the pH-dependent thiolate-specific absorbance of the catalytic cysteine. The pKa was obtained from the nonlinear fit
to the Henderson–Hasselbach equation. (b) Determination of the redox equilibria of MtbDsbAwith glutathione at pH 7.0 and 298 K. The plot shows the
averaged fraction (three replicates) of reduced MtbDsbA at various ratios of reduced:oxidized glutathione. The resulting equilibrium constantKeq (17.37
 0.1 mM) from the nonlinear curve fit for a one-site binding equation was used to calculate the redox potential of MtbDsbA relative to the glutathione
(GSH/GSSG) standard potential of 240 mV (Gilbert, 1995). (c) Relative thermal stability of oxidized (grey) and reduced (black) MtbDsbA at pH 7.0.
The normalized average far-UV CD signal from three measurements was fitted to a two-state unfolding model as described previously (Kurz et al., 2009).
The resulting melting temperature (Tm) of MtbDsbA shows that its reduced form (351.7  0.1 K) is more stable than its oxidized form (338.6  0.1 K).
We then set out to determine the redox-activity profile of
MtbDsbA in standard disulfide oxidase, reductase and
isomerase assays.
The disulfide oxidase activity of MtbDsbAwas investigated
using an in vitro peptide-oxidation assay with a fluorescently
labelled peptide substrate (CQQGFDGTQNSCK), using
GSSG as the electron donor to regenerate the oxidized DsbA
(Fig. 3a). MtbDsbA catalyzed peptide oxidation well above
the background rate [in the absence of enzyme or in the
presence of the catalytic cysteine mutant MtbDsbA
(Cys92Ala)]. However, EcDsbA-mediated peptide oxidation
was found to be faster than MtbDsbA as it required five times
more MtbDsbA to match the catalytic rate of EcDsbA. This
suggests the possibility that MtbDsbA and EcDsbA recognize
the substrate peptide with differing affinities or kinetics.
The reductase activity of MtbDsbA was assessed spectro-
photometrically by analyzing the ability of the enzyme to
reduce the interchain disulfides of insulin (measured as an
increase in turbidity through precipitation of the insulin B
chain; Fig. 3c). In contrast to EcDsbA, MtbDsbA did not show
any disulfide reductase activity against insulin, supporting the
possibility that the two enzymes have different substrate-
binding surfaces.
Finally, we tested the ability of MtbDsbA to isomerize, or
shuffle, the incorrect disulfides of scrambled RNaseA to form
the correctly folded RNaseA. Under the conditions of the
assay, MtbDsbA was able to generate just 10% of the activity
of fully folded RNaseA after 5 h (Fig. 3c). By comparison,
EcDsbA and EcDsbC (a disulfide isomerase enzyme)
produced 60 and 90%, respectively, of the activity of
correctly folded RNase over the same time period. These
observations are consistent with the view that MtbDsbA has
the characteristic redox properties of a disulfide oxidase but
differs functionally in other redox assays compared with the
prototypical EcDsbA oxidase.
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Figure 3
Disulfide oxidoreductase activities. (a) Disulfide oxidase activity. Representative fluorescence curves of peptide cysteine oxidation by MtbDsbA and
EcDsbA in the presence of glutathione as the electron donor. Enzyme-catalyzed peptide oxidation is significantly faster than the glutathione-mediated
reaction. Peptide oxidation in the buffer control or by the catalytically inactive MtbDsbA (Cys89Ala) or EcDsbA (Cys33Ala) was insignificant over the
duration of the assay (not shown for clarity). (b) Insulin disulfide-reduction assay. The precipitation of insulin by MtbDsbA or EcDsbA or DTT (trace
overlaps that of EcDsbA) was monitored as described in x2. (c) Scrambled RNase disulfide isomerization assay. Disulfide isomerization activity of
MtbDsbA, EcDsbA and EcDsbC was monitored using scrambled RNase as the substrate.
Figure 2
Ability of MtbDsbA to recognize EcDsbB. (a) Restoration of E. coli
motility. Constructs expressing MtbDsbA or EcDsbA (control) were
transformed into E. coli DsbA null (JCB817) and DsbA/DsbB double
null (JCB818) mutant cells. FlgI function is impaired in the absence of
EcDsbA or EcDsbB owing to the absence of disulfide-bonding activity
(Dailey & Berg, 1993). The ability to recognize EcDsbB and EcDsbA
substrates in vivo by MtbDsbA was evaluated by restoration of E. coli
motility in the agar, as seen in the induced EcDsbA control. Shown is the
summary of three replicates of induced (containing arabinose) and
uninduced bacterial swarming plates (not containing arabinose, as a
negative control). See Supplementary Fig. S2 for bacterial plate images.
(b) Ubiquinone reduction of EcDsbB–UQ1 by MtbDsbA. The data
presented here are the normalized mean absorbance of UQ1 from three
independent measurements. EcDsbB was added to the EcDsbA/UQ1
mixture to initiate the reaction.
3.4. The crystal structure of MtbDsbA reveals unique features
To explore the atomic details of MtbDsbA, we determined
its structure at 2.0 A˚ resolution. The structure was solved by
MR searches using trimmed ‘Poly Ser’ templates derived from
remote DsbA homologues (see x2 and Supplementary Fig.
S1). Two independent MtbDsbA molecules were well resolved
in the asymmetric unit (residues 57–255; 199 residues for each
monomer) and were refined to Rwork and Rfree values of 14.5
and 19.2%, respectively (Table 1). TheMtbDsbA structure has
a canonical DsbA-like architecture comprising a Trx domain
with a helical domain inserted into the middle of the Trx
domain (Fig. 4a). The two MtbDsbA molecules in the asym-
metric unit are very similar (r.m.s. deviation of 0.26 A˚ for all
C atoms). However, the structure of MtbDsbA differs
significantly from the prototypical EcDsbA with an r.m.s.
deviation of 3.7 A˚ for 149 C atoms (PDB entry 1fvk chain A;
3.7 A˚ for 148 C atoms for 1fvk chain B; Guddat et al., 1997).
Notable differences from EcDsbA include the folding
topology of the central -sheet, an additional helix H8 at the
C-terminus and a much shorter connecting loop between 5
and H7 (Fig. 4a) that forms part
of the binding interface between
EcDsbA and its redox partner
EcDsbB. As in all thioredoxin-
like proteins, the catalytic CXXC
motif is located at the N-terminus
of helix H1 in MtbDsbA.
A structural comparison of
MtbDsbA against all structures in
the PDB using DALI (Holm et
al., 2008) revealed similarities to
other DsbA structures, albeit
with relatively large r.m.s. devia-
tions (2.1–4.0 A˚ for 148–168 C
atoms) and weak sequence
conservation (Supplementary
Fig. S3). The closest structural
similarity occurs with DsbAs
from Gram-positive organisms:
BsDsbA (r.m.s. deviation 2.6 A˚
for 168 C atoms; 21% identity)
and SaDsbA (r.m.s. deviation
2.1 A˚ for 154 C atoms; 21%
identity). The central four strands
of the core -sheet have the same
topology (3–2–4–5) in the Trx
domains of this group of DsbAs.
However, a topological differ-
ence is noted in the arrangement
of strand 1 (Figs. 4 and 5a):
in MtbDsbA, BsDsbA and
WpDsbA1 1 forms hydrogen
bonds to 5 (3–2–4–5–1), whereas
in the majority of DsbA struc-
tures 1 forms hydrogen bonds to
3 on the opposite edge of the -
sheet (1–3–2–4–5).
A unique feature of MtbDsbA
compared with all other structu-
rally characterized DsbAs is the
C-terminal extension that forms
an additional helix, H8, that
packs against helices H1 and H7
(Figs. 4b and 5a). Crystallo-
graphic B factors plotted onto
these helices suggest the possibi-
lity that the H8 helix may reduce
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Figure 4
Structural comparison of MtbDsbA. (a) The crystal structure of MtbDsbA (left) is compared with the
prototypical EcDsbA (right; PDB entry 1fvk; Guddat et al., 1998). Catalytic/noncatalytic cysteine residues
are shown as light grey spheres. The noncatalytic structural disulfide of MtbDsbA is absent in EcDsbA.
Helix H8 appears to be unique to MtbDsbA. The orientation of helix H5 dramatically varies in these two
proteins. Gly204 breaks the hydrogen-bonding pattern in the middle of helix H6 of MtbDsbA (helix H6 is
kinked in MtbDsbA compared with EcDsbA). MtbDsbA appears to be much smaller in size than EcDsbA
in this orientation. However, the molecular surface areas of MtbDsbA (8208 A˚2) and EcDsbA (8670 A˚2)
are comparable. The intramolecular interaction of helix H1 with the C-terminal region of (b) MtbDsbA, (c)
EcDsbA (PDB entry 1fvk; Guddat et al., 1998) and (d) VcDsbA (PDB entry 1bed; Hu et al., 1997) is also
shown. For (b), (c) and (d) the backbone colour is set to the temperature factor from the PDB. The side
chains of interfacing residues identified by PISA (Protein Interfaces, Surfaces and Assemblies; Krissinel &
Henrick, 2007) analysis are shown as sticks. Catalytic and noncatalytic cysteines are shown as grey spheres.
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Figure 5
Structural elements of DsbAs and the catalytic site of MtbDsbA. (a) Structure-based sequence alignment of DsbAs. Structurally equivalent positions
(upper case), variable regions (lower case) and insertions (dashes) are shown. PknE DsbA sequence alignment is based on MtbDsbA and BsDsbA (see
Supplementary Fig. S6 for the PknE hypothetical model). Secondary-structure assignments for MtbDsbA (top green), EcDsbA (bottom blue) and
topological variations originating at strand 1 in MtbDsbA and EcDsbA (orange) are presented. The catalytic motif and cis-Pro motif are highlighted in
cyan and the equivalent EcDsbA residues involved in partner/substrate interaction are highlighted in orange. A negatively charged residue (Glu165) in
the vicinity of the catalytic cysteine, a residue blocking the hydrophobic groove (Trp226) and a noncatalytic structural disulfide bond are marked with red
arrows (see text for details). (b) The structure of the catalytic face of MtbDsbA. Residues forming the putative binding surface and negatively charged
residues neighbouring the catalytic cysteine are shown. The inset displays the 2mFo DFc electron-density map around the catalytic motif, the cis-Pro
loop and ordered active-site water molecules (1.0 contour level).
the mobility of the catalytic helix H1 in comparison to
EcDsbA and VcDsbA (Figs. 4b–4d). We then analyzed the
interface between helix H1 and the C-terminal H8 region
(Table 3). Compared with other structurally characterized
DsbAs, the presence of helix H8 in MtbDsbA buries a greater
proportion of helix H1 (buried surface area of 592 versus 401–
260 A˚2). The H8 helix interaction may restrict the conforma-
tional flexibility of helices H1 and H7. Similarly, the second
disulfide bond (Cys140–Cys192) of MtbDsbA that links
helices H2 and H5 may also restrict flexibility of the four-helix
bundle (Figs. 4 and 5a). The functional effects of these
conformational restrictions are unclear but might explain at
least in part the differences that we observe in the functional
assays for MtbDsbA and EcDsbA.
The highly conserved structural regions in these DsbAs are
the catalytic motif and cis-proline (cis-Pro) loop, both of which
are known to be critical for activity in other DsbA enzymes
(Kadokura et al., 2004). However, the catalytic motif (Cys89-
Pro90-Ala91-Cys92) in MtbDsbA differs from other structu-
rally characterized DsbAs, which are generally Cys-Pro-His/
Tyr/Ser-Cys. The catalytic cysteines Cys89 and Cys92 display
alternative side-chain conformations corresponding to
oxidized and reduced states (estimated approximately 50 and
65% for reduced states on the basis of crystallographic occu-
pancy), despite the fact that
oxidized protein was used for
crystal growth (Fig. 5b). The
active-site disulfides of DsbA
proteins are susceptible to radia-
tion damage in the crystal
(Guddat et al., 1998) and the
broken disulfide bond in
MtbDsbA is therefore likely to be
a result of the synchrotron
radiation used to measure the
diffraction data. In its reduced
form in the crystal, Cys89 of
MtbDsbA is likely to exist as the
thiolate (pKa 4.2, pH in the
crystal drop 5.5). Ordered active-
site water molecules are present
in the crystal structure at posi-
tions consistent with formation of
stabilizing hydrogen bonds to the
Cys89 thiolate and to Thr214, a
residue preceding the cis-Pro
loop. This hydrogen-bonding
network differs from that in
EcDsbA, which has a Val at the
equivalent position to Thr214, but
is similar to that in SaDsbA,
which also has a Thr prior to the
cis-Pro residue (Heras et al.,
2008).
3.5. The surface surrounding the
active site of MtbDsbA differs
from that of EcDsbA
The conformation and amino-
acid composition of the loop
connecting the Trx domain and
the helical domain (3–H2, L1),
an inter-helix loop (H3–H4, L2),
the cis-Pro loop (H6–4, L3) and
the connecting loop 5–H7 (L4)
create the surface features
surrounding the catalytic cysteine
(Cys89) of MtbDsbA (Fig. 5).
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Figure 6
Comparison of surface properties. (a) Hydrophobicity surface presentations for MtbDsbA and EcDsbA.
Surface colourings are mapped to the Kyte–Doolittle hydrophobicity scale from purple (most hydrophilic)
to white to tan (most hydrophobic). The MtbDsbA structure is shown (left) with the modelled VKOR
peptide (VPSCNV) and crystallographically identified artificial ligand 1,4-dioxane (see text and
Supplementary Fig. S4 for details). The EcDsbA–EcDsbB complex structure is shown on the right
(PDB entry 3e9j; Malojcic´ et al., 2008). For clarity only the periplasmic loop segment ‘PFATCDF’ of
EcDsbB is shown. Electrostatic surface comparisons of (b) MtbDsbA, (c) the hypothetical model of PknE
DsbA and (d) EcDsbA. Electrostatic surface potential is contoured between 6 (red) and +6 (blue) kT/e.
The homology model of PknE (template based on MtbDsbA and BsDsbA) was prepared inMODELLER
(Eswar et al., 2006) and atomic clashes were minimized in Chiron (Ramachandran et al., 2011).
Crystal structures of EcDsbA in complex with protein part-
ners have shown that the hydrophobic patch created by loops
L1 and L3, the active-site motif and the hydrophobic groove
formed by loop L4 and helix H1 contribute to interactions
with partner proteins (Paxman et al., 2009; Inaba et al., 2006).
The length and amino-acid identity of these loops are gener-
ally not conserved among DsbAs (Fig. 5a). The relatively long
L4 loop in EcDsbA creates a large hydrophobic groove
compared with the short loop found in MtbDsbA, SaDsbA
and BsDsbA (Fig. 6). In MtbDsbA, the side chain of Trp226
(L4 loop) sits in a shallow groove formed by Ile94, Phe95,
Gly98, Phe99, Ser227, Thr228 and Pro229 (Fig. 5b). The
hydrophobic nature of the surrounding catalytic residues is
largely preserved in MtbDsbA (Fig. 6). Unexpectedly, a
ligand, 1,4-dioxane from the crystallization solution, was
bound in this shallow groove, forming contacts with Ile94,
Gly98, Phe99 and Pro229 (Supplementary Fig. S4). MtbDsbA
also has two negatively charged residues near the catalytic
Cys89, similar to those observed in SaDsbA (Glu165 and
Glu225, see Fig. 5b). The SaDsbA glutamate equivalent to
Glu165 has been shown to influence the pKa of the catalytic
cysteine (Heras et al., 2008).
3.6. MtbDsbA binds a peptide derived from VKOR
Although the binding surface of MtbDsbA does not have
the distinct binding groove of EcDsbA that interacts with a
periplasmic loop of its membrane partner EcDsbB, we inves-
tigated whether a fragment of a periplasmic loop from the
putative binding partner MtbVKOR would interact with
MtbDsbA. We used ITC to assess the binding of MtbDsbA to
several peptides derived from MtbVKOR (see Supplementary
Fig. S5 for the quality of the ITC data). Topological prediction
indicated that MtbVKOR is comprised of five transmembrane
helices connected by two periplasmic loops. Cys57 from the
first periplasmic loop has been shown to form a mixed disul-
fide bond with EcDsbA (Wang et al., 2011), although a direct
interaction of MtbVKOR with any mycobacterial protein has
not been reported. We found that the MtbVKOR 11-residue
peptide segment surrounding Cys57 (51PIYVPSCNVNP61)
binds to MtbDsbA with an apparent Kd of 3.8 mM (Table 4).
Trimming from either end of this peptide showed that a
minimal hexapeptide (54VPSCNV59) binds to MtbDsbA with
Kd,app = 6.7 mM. Further, modelling of the
54VPSCNV59
peptide onto MtbDsbA suggested that Tyr53 of the VKOR
sequence might bind to the site occupied by 1,4-dioxane in the
crystal structure (Fig. 6a). Indeed, this heptapeptide
53YVPSCNV59 showed improved binding (Kd,app =2.9 mM) to
MtbDsbA. Binding of this VKOR peptide to MtbDsbA is
cysteine-dependent, as substitution of Cys with Ala or Leu or
mutation of the MtbDsbA catalytic Cys89 to Ala abolished
binding under the conditions tested.
3.7. Comparison with the predicted mycobacterial DsbA-like
domain of PknE
Aside from MtbDsbA, the H37Rv strain encodes five other
putative extracytoplasmic Trx-related proteins: DsbE
(Rv2878c), DsbF (Rv1677), Rv3673c, Rv0526 and the trans-
membrane protein kinase PknE (Rv1743). PknE is a clear
structural homologue of MtbDsbA and also contains a kinase
domain. Curiously, sequence searches suggest that PknE
orthologues are restricted to pathogenic mycobacteria and
PknE appears to be the only Mtb protein kinase fused to a
DsbA homologous domain. The PknE predicted DsbA
domain (residues 377–566) is linked to the intracellular
protein kinase domain (residues 1–289) through a single-pass
transmembrane helix (residues 337–359). Sequence compar-
ison and secondary-structure prediction are consistent with
the notion that PknE DsbA shares the same overall fold as
that of MtbDsbA. We generated a homology model for PknE
DsbA based on the MtbDsbA structure to compare the
sequence variation in the context of the three-dimensional
structure (Supplementary Fig. S6). Predicted differences from
MtbDsbA in the PknE DsbA domain include the absence of
helix H8 and a short helix H7 at the C-terminus. There are also
sequence variations in loops L1, L3 and L4 (Fig. 5a). Predicted
similarities in PknE DsbA include conservation of the Thr-cis-
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Table 3
Analysis of the interface between helix H1 and the C-terminal region of DsbA structures.
The buried surface area (BSA) in helix H1 (column 3) was determined using PISA analysis (Krissinel & Henrick, 2007). DsbAs, their PDB codes (column 1, in
parentheses) and the residue ranges in helix H1 (column 2, in parentheses) and the C-terminal region (column 4, in parentheses) included in the PISA analysis are
listed. The percentage of surface area buried in helix H1 relative to its total accessible surface area (2000 A˚2) is given in column 3 (in parentheses). For MtbDsbA
and EcDsbA, BSA and the values reported for the percentage of surface area buried are an average of two MtbDsbA chains (molecule 1 and molecule 2 in the
asymmetric unit) and nine EcDsbA chains [PDB entries 1dsb (two chains; Martin et al., 1993), 1fvk (two chains; Guddat et al., 1997), 1a2m (two chains; Guddat et
al., 1998), 1a2l (two chains; Guddat et al., 1998) and 1a2j (one chain; Guddat et al., 1998)].
Protein (PDB code)
No. of interfacing
residues in helix H1 Helix H1 BSA (A˚2)
No. of interfacing residues
in C-terminal region
MtbDsbA 13 (89–109) 592  4 (29.6) 18 (226–255)
EcDsbA 9 (30–50) 401  42 (18.9) 10 (168–188)
BsDsbA (3eu3; Crow et al., 2009) 8 (69–91) 355 (15.9) 8 (205–222)
SaDsbA (3bci; Heras et al., 2008) 9 (26–46) 370 (15.8) 7 (167–178)
PaDsbA (3h93; Shouldice et al., 2010) 7 (37–55) 282 (14.3) 9 (166–192)
VcDsbA (1bed; Hu et al., 1997) 8 (30–48) 261 (13.7) 6 (164–181)
WpDsbA (3f4r; Kurz et al., 2009) 9 (51–71) 363 (16.5) 9 (196–218)
NmDsbA1 (3a3t; Vivian et al., 2009) 7 (57–74) 290 (15.5) 7 (189–212)
Pro motif, a glutamate equivalent of Glu225 and a tyrosine
equivalent of Trp226. The calculated electrostatic potential
surfaces are negative in the region surrounding the catalytic
site in both proteins (Figs. 6c and 6d). However, the CPPC
catalytic motif in PknE DsbA differs from that of CPAC of
MtbDsbA. These differences may contribute to a difference in
redox characteristics. In EcDsbA, mutation of CPHC to CPPC
dramatically increased its reducing potential (122 mV to
220 mV; Bessette et al., 2001). The native CPPC active site in
a DsbA homologue from Salmonella enterica (SeSrgA) has
also been linked to a more strongly reducing potential
(154 mV). Indeed, the insulin reductase activity of SeSrgA
was shown to be similar to that of the disulfide isomerase
EcDsbC (Heras et al., 2010).
4. Discussion
Novel drug targets are desperately needed to combat tuber-
culosis. Mycobacterial proteins exported across the cyto-
plasmic membrane play important roles in Mtb adhesion,
invasion, virulence, pathogenesis and survival inside host cells.
Drugs targeting export systems in Gram-negative bacteria
have been tested for their ability to block delivery of effector
proteins required for virulence (Moir et al., 2011). Likewise,
there are intensive efforts to develop antituberculosis drugs
that target the major mycobacterial protein-export systems:
the Sec pathway, the Tat pathway and the ESX pathways
(Feltcher et al., 2010; McCann et al., 2011).
Another approach is to target the disulfide pathways that
mediate disulfide-bond formation and correct folding of
exported proteins in Mtb (Chim et al., 2010, 2011; Goulding et
al., 2004). In bacteria, disulfide-bond formation in newly
exported proteins is commonly mediated through mechanisms
that rely on electron transfer between redox proteins. The
best-studied protein redox pair, DsbA/DsbB, is found in most
aerobic -, - and -proteobacteria. However, in myco-
bacteria and other actinobacteria, cyanobacteria and - and "-
proteobacteria, it has been proposed that DsbA/VKOR forms
a functional redox pair to catalyze disulfide-bond formation
(Dutton et al., 2008; Li et al., 2010; Wang et al., 2011). The
currently accepted mechanism is that the cysteine-containing
periplasmic loop of transmembrane protein DsbB or VKOR is
transiently drawn into the binding groove of DsbA (Fig. 6) to
drive the flow of electrons (Inaba & Ito, 2008). Oxidized DsbA
then exchanges its catalytic disulfide bond with newly
exported proteins by transiently interacting with them through
its catalytic cysteine and binding surface (Inaba & Ito, 2008;
Inaba et al., 2006; Kadokura et al., 2003). Thus, compounds
targeting the protein–protein interaction surface responsible
for interaction between DsbA and its substrate proteins or
between DsbA and DsbB/VKOR may inhibit virulence-factor
maturation in pathogens.
The data we present here show that Rv2969c has disulfide
oxidase activity, a highly acidic active-site cysteine, a desta-
bilizing active-site disulfide and a highly oxidizing potential.
Structurally, MtbDsbA has a canonical DsbA architecture
with a CXXC active-site motif. We therefore conclude that
Mtb Rv2969c is an authentic DsbA enzyme. Our data also
show that MtbDsbA is able to interact tightly with a seven-
residue peptide corresponding to the periplasmic loop of
MtbVKOR and these data support the notion that MtbDsbA
and MtbVKOR are a functional redox pair that could catalyze
disulfide-bond formation in newly translocated substrates.
Helix H8 at the C-terminus of MtbDsbA and its interaction
with active-site helix H1 are unique to MtbDsbA among
structurally characterized DsbAs. This feature appears to be
absent in the DsbA-like domain of PknE. Substrate binding
and mobility of DsbAs has been linked to the catalytic activity
of DsbA (Horne et al., 2007). In this context, restraint of helix
H1 by helix H8 in MtbDsbA may contribute to the catalytic
activity of MtbDsbA. Moreover, the relatively negative
surface potential surrounding the catalytic site of MtbDsbA
compared with EcDsbA suggests that these two enzymes have
very different substrate-binding specificities. This is supported
by our assay data showing the relative activities of these two
enzymes in assays for reductase (MtbDsbA no activity),
oxidase (MtbDsbA slower activity) and isomerase (MtbDsbA
marginal activity) activity. EcDsbA is known to be a promis-
cuous enzyme that interacts with many substrates. Our struc-
tural and functional data suggest that MtbDsbA may have a
more limited number of specific substrates.
Previous work has shown that the anticoagulant warfarin
that inhibits human VKOR can also inhibit MtbVKOR and it
interferes with the growth of Mtb in cell studies (Dutton et al.,
2010). Inhibiting MtbVKOR is an appealing strategy for
treating Mtb, but will require the design of selective inhibitors
that target MtbVKOR and not its human counterpart. Our
results suggest that MtbDsbA may represent an alternative
target for inhibiting disulfide oxidation in Mtb and for
preventing the production of virulence factors.
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Table 4
Thermodynamic parameters for VKOR-derived peptides binding to
MtbDsbA.
Kd,app, apparent dissociation constant; H, enthalpy change; TS, tempera-
ture (K) entropy change; N is the apparent stoichiometry. TS is calculated
from the free energy equation (H  TS = RTlnKd,app). Values reported
are the mean and standard deviation of the curve fits from two ITC runs in
each case. Representative ITC profiles are provided in Supplementary Fig. S5.
n.b., no binding detected. 1 cal = 4.184 J.
N
Kd,app
(mM)
H
(kcal mol1)
TS
(kcal mol1)
PIYVPSCNVNP 1.0 3.8  0.2 10.9  0.0 3.5
VPSCNVNP 1.0 5.9  2.6 7.1  4.0 2.5
VPSCNV 1.0 6.7  0.0 6.8  0.2 0.1
VPSLNV n.b.
YVPSCNV 1.1 2.9  0.3 7.0  0.4 0.5
YVPSANV n.b.
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